Cambridge’s Aveo Pharmaceuticals Inc. rose on its offering of 6.7 million shares for $7.50 each. The company said it expects to raise about $50 million before discounts and commissions. The offering is expected to close on Wednesday. Aveo helped develop an experimental cancer pill — Tivopath — that is currently under review by the Food and Drug Administration to treat advanced kidney cancer. The agency is expected to finish its review by July.
Aveo expects to raise $50m in offering
You have reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week